BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI's Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug (RLD) Trental®. The current annual U.S. market for Pentoxifylline ER Tablets is approximately $19.7 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. "We are pleased ...

The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.17, reflecting a +1.37% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.22% gain on the day. At the same time, the Dow added 0.36%, and the tech-heavy Nasdaq gained 0.32%.The drugmaker's stock has climbed by 3.71% in the past month, exceeding the Medical sector's gain of 2.3% and the S&P 500's gain of 1.61%.Analysts and investors alike will be keeping a close eye on the performance of A ...

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $55.41, moving -0.32% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.23%. On the other hand, the Dow registered a gain of 1.06%, and the technology-centric Nasdaq increased by 1.7%.Coming into today, shares of the drugmaker had gained 4.63% in the past month. In that same time, the Medical sector gained 3.16%, while the S&P 500 gained 0.94%.The investment community will be closely monitoring ...

BAUDETTE, Minn., Jan. 16, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Indomethacin Oral Suspension (OS), USP. ANI's Indomethacin OS is the generic version of the Reference Listed Drug (RLD) Indocin® Oral Suspension. The current annual U.S. market for Indomethacin OS is approximately $4.1 million, according to the latest estimates fro ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Participants Les Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Operator Good day, everyone, and welcome to the ANI Pharmaceuticals, Inc. Third Quarter 2023 Earnings Results Call. At this time, all participants are in a listen- ...

Table of Contents Large accelerated filer o Accelerated filer x Non-accelerated filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Participants Vamil Divan - Guggenheim Securities Les Sulewski - Truist Securities Operator Good morning, everyone. My name is Chelsea and I will be your conference operator. At this time, I would like to welcome everyone to ANI Pharmaceuticals Second Quarter 2023 Financial Res ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other j ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications Investor Relations Nikhil Lalwani - President and Chief Executive Officer Stephen Carey - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Vamil Divan - Guggenheim Securities Brandon Folkes - Cantor Fitzgerald Greg Fraser - Truist Securities Oren Livnat - H.C. Wainwright Operator Good day, everyone, and welcome to toda ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other ...